152 related articles for article (PubMed ID: 21042216)
21. Acute effects of high-density lipoproteins: biochemical basis and clinical findings.
Chiesa G; Parolini C; Sirtori CR
Curr Opin Cardiol; 2008 Jul; 23(4):379-85. PubMed ID: 18520723
[TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.
Osei-Hwedieh DO; Amar M; Sviridov D; Remaley AT
Pharmacol Ther; 2011 Apr; 130(1):83-91. PubMed ID: 21172387
[TBL] [Abstract][Full Text] [Related]
23. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
[TBL] [Abstract][Full Text] [Related]
24. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
[TBL] [Abstract][Full Text] [Related]
25. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
Li M; Liu ZM
Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management.
Shah PK; Chyu KY
Trends Cardiovasc Med; 2005 Nov; 15(8):291-6. PubMed ID: 16297766
[TBL] [Abstract][Full Text] [Related]
27. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
Linsel-Nitschke P; Tall AR
Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
29. The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?
Heinecke JW
Nat Med; 2012 Sep; 18(9):1346-7. PubMed ID: 22961165
[No Abstract] [Full Text] [Related]
30. Your health in the 21st century. Fine-tuning heart health.
Sacks FM; Skerrett PJ
Newsweek; 2005; 145(26A):22-3. PubMed ID: 16375135
[No Abstract] [Full Text] [Related]
31. Is raising HDL a futile strategy for atheroprotection?
Joy T; Hegele RA
Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.
Wolska A; Reimund M; Sviridov DO; Amar MJ; Remaley AT
Cells; 2021 Mar; 10(3):. PubMed ID: 33800446
[TBL] [Abstract][Full Text] [Related]
33. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.
Imaizumi S; Navab M; Morgantini C; Charles-Schoeman C; Su F; Gao F; Kwon M; Ganapathy E; Meriwether D; Farias-Eisner R; Fogelman AM; Reddy ST
Circ J; 2011; 75(7):1533-8. PubMed ID: 21628835
[TBL] [Abstract][Full Text] [Related]
34. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
35. Antioxidants and cardiovascular disease.
Violi F; Cangemi R
Curr Opin Investig Drugs; 2005 Sep; 6(9):895-900. PubMed ID: 16187689
[TBL] [Abstract][Full Text] [Related]
36. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.
Leman LJ; Maryanoff BE; Ghadiri MR
J Med Chem; 2014 Mar; 57(6):2169-96. PubMed ID: 24168751
[TBL] [Abstract][Full Text] [Related]
37. Recombinant high-density lipoproteins and their use in cardiovascular diseases.
Cao YN; Xu L; Han YC; Wang YN; Liu G; Qi R
Drug Discov Today; 2017 Jan; 22(1):180-185. PubMed ID: 27591840
[TBL] [Abstract][Full Text] [Related]
38. The role of dysfunctional HDL in atherosclerosis.
Navab M; Reddy ST; Van Lenten BJ; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S145-9. PubMed ID: 18955731
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein A-I mimetic peptides.
Van Lenten BJ; Wagner AC; Anantharamaiah GM; Navab M; Reddy ST; Buga GM; Fogelman AM
Curr Atheroscler Rep; 2009 Jan; 11(1):52-7. PubMed ID: 19080728
[TBL] [Abstract][Full Text] [Related]
40. Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering.
Derdemezis CS; Filippatos TD; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):120-34. PubMed ID: 20200328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
